INAB — IN8BIO, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1740279 ·
Last close
$0.82
Market Cap
$8.86M
52W High
$2.73
52W Low
$0.72
ADV30
205,510
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -4,721,000 | -4,592,000 | 18,695,000 | 13,973,000 | 4,521,000 |
| Jun 2026 | 0 | — | -4,935,000 | -4,781,000 | 21,745,000 | 17,956,000 | 3,382,000 |
| Mar 2026 | 0 | — | -5,266,000 | -5,090,000 | 26,265,000 | 21,941,000 | 3,484,000 |
| Dec 2025 | 0 | — | -5,033,000 | -4,942,000 | 32,282,000 | 27,092,000 | 4,724,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,355,000
Investing CF
$-242,000
Financing CF
$19,232,000
CapEx
$-242,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.60
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-150,967,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-19,201,000
Pretax Income TTM
$-18,667,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,861,000 | -19,440,000 | 32,282,000 | 4,724,000 | 27,558,000 | -12,712,000 |
| Dec 2024 | 0 | -29,599,000 | -30,437,000 | 20,944,000 | 6,466,000 | 14,478,000 | -24,149,000 |
| Dec 2023 | 0 | -30,007,000 | -30,007,000 | 33,709,000 | 8,772,000 | 24,937,000 | -23,340,000 |
| Dec 2022 | 0 | -28,521,000 | -28,521,000 | 33,039,000 | 10,307,000 | 22,732,000 | -24,121,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$534,000
NetIncome TTM
$-18,667,000
OpCashFlow TTM
—
Assets (Latest)
$21,745,000
Forward EPS
$-0.95
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INTS | INTENSITY THERAPEUTICS, INC. | $8.81M | $2.67 | — |
| TCRX | TScan Therapeutics, Inc. | $9.59M | $0.15 | — |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $9.72M | $0.88 | — |
| CUBT | Curative Biotechnology Inc | $7.56M | $0.85 | — |
| ALGS | Aligos Therapeutics, Inc. | $7.40M | $1.36 | — |
News headlines (Yahoo Finance, 1h cache)
IN8bio Reports Updated Glioblastoma Data at SNO 2026 Demonstrating Median Overall Survival of 20.9 Months and 50% Two-Year Survival with Gamma-Delta T Cell Therapy
2026-11-16 13:00 · Yahoo
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:01 · Yahoo
IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-05 21:01 · Yahoo
IN8bio to Present at Sidoti Small-Cap Virtual Conference
2026-09-22 20:00 · Yahoo
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
2026-09-09 12:00 · Yahoo
IN8bio Reports Second Quarter 2026 Financial Results and Recent Business Highlights
2026-08-06 20:01 · Yahoo
IN8bio Announces Publication in The Journal of Clinical Oncology Demonstrating DeltEx™ DRI Doubles Progression-Free Survival in Newly Diagnosed Glioblastoma
2026-07-09 12:00 · Yahoo
IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
2026-05-07 20:30 · Yahoo
IN8bio to Showcase Next-Generation T Cell Engager Platform and New Clinical Data at Upcoming R&D Day and Medical Conferences
2026-05-06 12:00 · Yahoo
IN8bio Presents New Translational Data Demonstrating DeltEx DRI Reshapes the Immune Landscape in Glioblastoma
2026-05-14 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.